February 10, 2010
The Spiegel Research Group has recently made important strides in their work involving antibody-recruiting small molecules that target HIV and prostate cancer. These molecules function by redirecting antibodies present in the human bloodstream to proteins expressed on the surface of human pathogens, and represent novel and potentially general strategies for disease treatment. These studies were recently published in JACS, and have been highlighted in various venues, including ACS Chemical Biology, Faculty of 1000 Biology, Popular Science, R&D Magazine, e! Science News, Science Daily, Genetic Engineering & Biotechnology News, & ACS Noteworthy Chemistry.